European Studies Help Plan A Path Forward For Value Added Medicines
Six value added medicines case studies across six European countries are featured in the latest IQVIA report for Medicines for Europe. Each of them, according to the association’s sector chair Arun Narayan, helps point to a way forward for value added medicines in Europe.
You may also be interested in...
Belgium’s recent royal decree on pharmaceutical reimbursement represents “three significant steps forward for the generic medicines sector”, according to local off-patent industry association FeBelGen. As well as simplifying reimbursement, the association points out, the decree also sets out a reimbursement pathway for value-added medicines as well as removing certain packaging requirements.
From 20 October, a free online platform will allow registrants attending the digital Global Generics & Biosimilars Awards 2020 to participate in two weeks of dedicated networking activities ahead of the ceremony on 3 November.
In this podcast discussion, Generics Bulletin editor David Wallace talks to Duncan Emerton, director of Custom Intelligence and Analytics for Informa Pharma Intelligence, about the UK's new licensing procedure for biosimilars.